BioPharma Resources

Investigational drug · Phase 2

EVO756

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Migraine, Chronic Inducible Urticaria, Atopic Dermatitis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

4

1 still active

All registered trials

4

Any phase or sponsor naming "EVO756"

First trial start

2024

Aug 14, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "EVO756", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Migraine
  • Chronic Inducible Urticaria
  • Atopic Dermatitis
  • Chronic Spontaneous Urticaria

Approved drugs for the same conditions: Migraine · Atopic dermatitis (eczema) · Chronic hives (urticaria) · Neurology · Immunology and inflammation · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "EVO756" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Migraine

  • AXS-07meloxicam-rizatriptanPhase 31 trial

    Axsome Therapeutics, Inc. · Migraine

  • BHV-2100Phase 21 trial

    Biohaven Therapeutics Ltd. · Migraine

  • MEDI0618Phase 21 trial

    AbbVie · Migraine

  • MTX101Phase 21 trial

    Manistee Therapeutics · Migraine

  • PRT-064040Phase 21 trial

    Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.